Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

NCT04186871 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

119

Enrollment

INDUSTRY

Sponsor class

Conditions

Autoimmune Disorder
Rheumatoid Arthritis
Systemic Lupus Erythematosus
Primary Sjögren's Syndrome

Interventions

DRUG: branebrutinib
DRUG: abatacept
DRUG: branebrutinib placebo

Sponsor

Bristol-Myers Squibb